Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Australasian journal of dermatology 2024-06, Vol.65 (4), p.e111-e113
Hauptverfasser:	Salvia, Giorgia, Bevilacqua, Matteo, Manzo Margiotta, Flavia, Michelucci, Alessandra, Granieri, Giammarco, Fidanzi, Cristian, Dini, Valentina, Romanelli, Marco, Mazzatenta, Carlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - adverse effects Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use brodalumab Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Drug Substitution Female hidradenitis suppurativa Humans Male Middle Aged Monoclonal antibodies paradoxical reaction psoriasis Psoriasis - drug therapy Pyoderma Pyoderma gangrenosum Pyoderma Gangrenosum - chemically induced Pyoderma Gangrenosum - drug therapy Trigger factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!